Targeting CGRP and 5‐HT 1F Receptors for the Acute Therapy of Migraine: A Literature Review
Headache The Journal of Head and Face Pain2019Vol. 59(S2), pp. 3–19
Citations Over TimeTop 10% of 2019 papers
Abstract
Current available therapies have either been nonspecific or had important limitations, including in patients with cardiovascular risk factors. Phase III clinical trials of lasmiditan, rimegepant and ubrogepant all met their primary endpoints, so the options for migraine-targeted acute therapy will likely soon increase.
Related Papers
- → Switching patients with migraine from sumatriptan to other triptans increases primary care costs(2004)17 cited
- → Infrequent or Non-Response to Oral Sumatriptan does not Predict Response to Other Triptans—Review of Four Trials(2005)54 cited
- → Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine(2012)33 cited
- → Sumatriptan: a decade of use and experience in the treatment of migraine(2004)25 cited
- [Sumatriptan plus naproxen for acute migraine attacks in adults].(2014)